These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 16434184)

  • 21. The workings of the amyloid diseases.
    Bellotti V; Nuvolone M; Giorgetti S; Obici L; Palladini G; Russo P; Lavatelli F; Perfetti V; Merlini G
    Ann Med; 2007; 39(3):200-7. PubMed ID: 17457717
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Conformational properties of the aggregation precursor state of HypF-N.
    Campioni S; Mossuto MF; Torrassa S; Calloni G; de Laureto PP; Relini A; Fontana A; Chiti F
    J Mol Biol; 2008 Jun; 379(3):554-67. PubMed ID: 18466920
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Crystallographic structure of the SH3 domain of the human c-Yes tyrosine kinase: loop flexibility and amyloid aggregation.
    Martín-García JM; Luque I; Mateo PL; Ruiz-Sanz J; Cámara-Artigas A
    FEBS Lett; 2007 May; 581(9):1701-6. PubMed ID: 17418139
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Structural disorder in amyloid fibrils: its implication in dynamic interactions of proteins.
    Tompa P
    FEBS J; 2009 Oct; 276(19):5406-15. PubMed ID: 19712107
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Consensus features in amyloid fibrils: sheet-sheet recognition via a (polar or nonpolar) zipper structure.
    Zheng J; Ma B; Nussinov R
    Phys Biol; 2006 Oct; 3(3):P1-4. PubMed ID: 17021379
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Design of mechanism-based inhibitors of transthyretin amyloidosis: studies with biphenyl ethers and new structural templates.
    Gupta S; Chhibber M; Sinha S; Surolia A
    J Med Chem; 2007 Nov; 50(23):5589-99. PubMed ID: 17948976
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Monitoring the prevention of amyloid fibril formation by alpha-crystallin. Temperature dependence and the nature of the aggregating species.
    Rekas A; Jankova L; Thorn DC; Cappai R; Carver JA
    FEBS J; 2007 Dec; 274(24):6290-304. PubMed ID: 18005258
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A molecular dynamics approach to the structural characterization of amyloid aggregation.
    Cecchini M; Curcio R; Pappalardo M; Melki R; Caflisch A
    J Mol Biol; 2006 Apr; 357(4):1306-21. PubMed ID: 16483608
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interpreting the aggregation kinetics of amyloid peptides.
    Pellarin R; Caflisch A
    J Mol Biol; 2006 Jul; 360(4):882-92. PubMed ID: 16797587
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nano-scale imaging and dynamics of amylin-membrane interactions and its implication in type II diabetes mellitus.
    Cho WJ; Jena BP; Jeremic AM
    Methods Cell Biol; 2008; 90():267-86. PubMed ID: 19195555
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Amyloid fibril formation and chaperone-like activity of peptides from alphaA-crystallin.
    Tanaka N; Tanaka R; Tokuhara M; Kunugi S; Lee YF; Hamada D
    Biochemistry; 2008 Mar; 47(9):2961-7. PubMed ID: 18232642
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High-pressure studies on protein aggregates and amyloid fibrils.
    Kim YS; Randolph TW; Seefeldt MB; Carpenter JF
    Methods Enzymol; 2006; 413():237-53. PubMed ID: 17046400
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular mechanism based on self-replicating protein conformation for the inheritance of acquired information in humans.
    Maury CP
    Med Hypotheses; 2006; 67(5):1164-9. PubMed ID: 16824696
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Alpha-sheet: The toxic conformer in amyloid diseases?
    Daggett V
    Acc Chem Res; 2006 Sep; 39(9):594-602. PubMed ID: 16981675
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fitting neurological protein aggregation kinetic data via a 2-step, minimal/"Ockham's razor" model: the Finke-Watzky mechanism of nucleation followed by autocatalytic surface growth.
    Morris AM; Watzky MA; Agar JN; Finke RG
    Biochemistry; 2008 Feb; 47(8):2413-27. PubMed ID: 18247636
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Peptide and protein mimetics inhibiting amyloid beta-peptide aggregation.
    Takahashi T; Mihara H
    Acc Chem Res; 2008 Oct; 41(10):1309-18. PubMed ID: 18937396
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Aging and transthyretin-related amyloidosis: pathologic examinations in pulmonary amyloidosis.
    Ueda M; Ando Y; Haraoka K; Katsuragi S; Terasaki Y; Sugimoto M; Sun X; Uchino M
    Amyloid; 2006 Mar; 13(1):24-30. PubMed ID: 16690497
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Importance of molecular computer modeling in anticancer drug development.
    Geromichalos GD
    J BUON; 2007 Sep; 12 Suppl 1():S101-18. PubMed ID: 17935268
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Analysis of molecular recognition features (MoRFs).
    Mohan A; Oldfield CJ; Radivojac P; Vacic V; Cortese MS; Dunker AK; Uversky VN
    J Mol Biol; 2006 Oct; 362(5):1043-59. PubMed ID: 16935303
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Computational analysis of the S. cerevisiae proteome reveals the function and cellular localization of the least and most amyloidogenic proteins.
    Tartaglia GG; Caflisch A
    Proteins; 2007 Jul; 68(1):273-8. PubMed ID: 17407164
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.